未知生产厂商
Sebelipase alfa is a recombinant lysosomal acid lipase used to treat lysosomal acid lipase deficiency.
Sebelipase alfa is a recombinant lysosomal acid lipase used to treat lysosomal acid lipase deficiency.
Lysosomal acid lipase (LAL) deficiency is an inherited storage disorder caused by a genetic defect that results in a marked decrease or loss in activity of the LAL enzyme. Endogenous LAL is found in the lysosome and is responsible for the breakdown of lipids - a deficiency of these enzymes results in the accumulation of cholesteryl esters and triglycerides, which lead to a number of downstream consequences such as progressive liver disease, malabsorption, and growth failure. Dyslipidemia associated with LAL deficiency may also result in the typical cardiovascular effects associated with elevated lipid levels. Sebelipase alfa is a recombinant form of human lysosomal acid lipase (rhLAL) which binds to cell surface receptors via glycans expressed on the protein and is subsequently internalized into lysosomes. From within the lysosome, sebelipase alfa catalyzes the lysosomal hydrolysis of cholesteryl esters and triglycerides to free cholesterol, glycerol and free fatty acids.
Sebelipase alfa is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency.
共 1 项相关疾病
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物,而非通用名;且专利申请在提交约 18 个月后才公开,较新的药物可能尚未出现在这里。